Iterum Therapeutics plc IPO Research Information

Iterum Therapeutics plc IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Iterum Therapeutics plc, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Iterum Therapeutics plc	ITRM - NASDAQ	$14.00-$16.00	$13.00	$12.70	6.2 million	5/25/2018
Underwriter(s): Leerink Partners, RBC Capital Partners
Co-Manager(s): Guggenheim Securities, Needham & Co.
Industry: Health Care
Filing(s): Filed 2018-05-01 Terms Added 2018-05-16 Final Prospectus 2018-05-25

Iterum Therapeutics plc Quote & Chart - Click for current quote - ITRM

About Iterum Therapeutics plc (adapted from Iterum Therapeutics plc prospectus):
They are a pharmaceutical company dedicated to developing and commercializing sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available globally.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ITRM" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.